RUBICON — Rubicon Research Share Price
Last trade - 00:00- IN₹104.75bn
- IN₹108.63bn
- IN₹12.84bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 37.8 | ||
| PEG Ratio (f) | 1.56 | ||
| EPS Growth (f) | 31.93% | ||
| Dividend Yield (f) | 0.26% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 16.18 | ||
| Price to Tang. Book | 17.76 | ||
| Price to Free Cashflow | 117.76 | ||
| Price to Sales | 6.05 | ||
| EV to EBITDA | 29.33 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 36.18% | ||
| Return on Equity | 38.85% | ||
| Operating Margin | 18.57% | ||
Financial Summary
| Year End 31st Mar | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | IN₹m | n/a | 3,135.67 | 3,935.19 | 8,538.89 | 12,842.72 | 17,270 | 22,734 | 60% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | +51.08 | +24.8 | +34.56 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Rubicon Research Ltd is an India-based pharmaceutical formulations company, which is focused on research and development, with a portfolio of specialty products and drug-device combination products targeting regulated markets, and particularly the United States. Its portfolio spans multiple dosage forms, including oral solids, oral liquids, nasal, and topical. Its technologies include RubiReten and RubiSRL. Its services include intellectual property evaluation and product design, formulation research development, analytical research development, technology transfer, dossier compilation and regulatory support, and clinical trials supplies. Its products are spread across many therapeutic areas, such as Analgesics/Pain Management, CVS, CNS, Hypokalemia, Skeletal Muscle Relaxants, NRT, Gastrointestinal, Metabolic, Immunosuppressant, and others. Others include Antipyretic, Hormonal Products, Diuretic, Antimuscarinics, Oral Rehydration Therapy, Over the Counter products, and Respiratory.
Directors
- Last Annual
- March 31st, 2025
- Last Interim
- September 30th, 2025
- Incorporated
- May 6th, 1999
- Public Since
- October 16th, 2025
- No. of Employees
- 1,141
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- National Stock Exchange of India
- Shares in Issue
- 164,750,309
- Address
- THANE, 400604
- Web
- https://www.rubicon.co.in/
- Phone
- +91 2261414000
- Contact
- Deepashree Tanksale
- Auditors
- Deloitte Haskins & Sells LLP
Similar to RUBICON
Biocon
National Stock Exchange of India
Indo US Bio-Tech
National Stock Exchange of India
Onesource Specialty Pharma
National Stock Exchange of India
Suven Life Sciences
National Stock Exchange of India
Syngene International
National Stock Exchange of India
FAQ
As of Today at 22:00 UTC, shares in Rubicon Research are trading at IN₹635.80. This share price information is delayed by 15 minutes.
Shares in Rubicon Research last closed at IN₹635.80 and the price had moved by over the past 365 days. In terms of relative price strength the Rubicon Research share price has matched the S&P BSE 100 Index by over the past year.
The overall consensus recommendation for Rubicon Research is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreRubicon Research does not currently pay a dividend.
Rubicon Research does not currently pay a dividend.
Rubicon Research does not currently pay a dividend.
To buy shares in Rubicon Research you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of IN₹635.80, shares in Rubicon Research had a market capitalisation of IN₹104.75bn.
Here are the trading details for Rubicon Research:
- Country of listing: India
- Exchange: NSI
- Ticker Symbol: RUBICON
Based on an overall assessment of its quality, value and momentum Rubicon Research is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Rubicon Research is IN₹780.00. That is 22.68% above the last closing price of IN₹635.80.
Analysts covering Rubicon Research currently have a consensus Earnings Per Share (EPS) forecast of IN₹13.60 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Rubicon Research. Over the past six months, its share price has matched the S&P BSE 100 Index by .
As of the last closing price of IN₹635.80, shares in Rubicon Research were trading -0.92% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Rubicon Research PE ratio based on its reported earnings over the past 12 months is 37.8. The shares last closed at IN₹635.80.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Rubicon Research's directors